Search

Displaying results 3071 - 3080 of 4335 in total
  1. Drug

    Menthyl salicylate

    go.drugbank.com/drugs/DB11201
    Approved

    Menthyl salicylate is an ester of menthol and salicylic acid . This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) .

  2. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions . Prezatide is used in cosmetic products for the skin and hair. It is known to aid wound healing and its potential appl...

  3. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells. Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF, which is a critical plasma glycop...

  4. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

  5. Drug

    Cloxacillin

    go.drugbank.com/drugs/DB01147
    ApprovedInvestigationalVet approved

    A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.

  6. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and t...

  7. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

  8. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condit...

  9. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

    Products: TOLTERODINA MYLAN GENERICS, TOLTERODINA DOC GENERICI
  10. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Renal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.